Determining the burden of respiratory syncytial virus disease: the known and the unknown

July 7, 2017 at 8:01 am

Lancet July 8, 2017 V.390 N.10090

Comment

Ruth A Karron, Robert E Black

60 years ago, respiratory syncytial virus (RSV) was identified in children admitted to hospital in Baltimore, MD, USA, with bronchiolitis or pneumonia.1 Since that time, RSV has been established as a leading cause of acute lower respiratory illness (ALRI) in infants and children living in all regions of the world.2, 3, 4, 5 As the widespread use of Haemophilus influenzae type b and pneumococcal conjugate vaccines decreases the burden of bacterial pneumonia in children, the proportional contribution of RSV to childhood ALRI will continue to increase. Substantial effort is being put into RSV disease prevention; more than 15 RSV vaccines and vaccine-like monoclonal antibodies (mAbs) are currently being assessed in clinical trials…

FULL TEXT

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31476-9/fulltext?elsca1=etoc

PDF

http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)31476-9.pdf

Advertisements

Entry filed under: Biología Molecular, Epidemiología, Infecciones respiratorias, Metodos diagnosticos, Sepsis, Update.

Coagulase-negative staphylococci. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study


Calendar

July 2017
M T W T F S S
« Jun   Aug »
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Most Recent Posts


%d bloggers like this: